National Institute for Health and Clinical Excellence

[1]  S. Feldman,et al.  Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. , 2007, Journal of the American Academy of Dermatology.

[2]  J. Byrd,et al.  Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. , 2007 .

[3]  L. Naldi,et al.  The clinical spectrum of psoriasis. , 2007, Clinics in dermatology.

[4]  J. Bergh,et al.  Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[6]  F. O'Malley,et al.  Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer , 2007, Current oncology.

[7]  C. Griffiths,et al.  Pathogenesis and clinical features of psoriasis , 2007, The Lancet.

[8]  U. Germing,et al.  Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.

[9]  P Geusens,et al.  Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. , 2007, Rheumatology.

[10]  J. Haerting,et al.  Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis , 2007 .

[11]  M. Dowsett,et al.  Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.

[12]  P. Emery,et al.  Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. , 2007, Arthritis and rheumatism.

[13]  J Raftery,et al.  A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. , 2007, Health technology assessment.

[14]  E. Sezer,et al.  Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema: incorrect assertion of treatment equivalence (response to Saleem Mustafa Taibjee) , 2007, Photodermatology, photoimmunology & photomedicine.

[15]  A. Gottlieb,et al.  A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. , 2007, Journal of the American Academy of Dermatology.

[16]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[17]  K. Reich,et al.  Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center study , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[18]  S. Al-Batran,et al.  Chemotherapy for advanced gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[20]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[21]  A. Gottlieb,et al.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. , 2007, Journal of the American Academy of Dermatology.

[22]  A. Silman,et al.  Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. , 2007, Arthritis and rheumatism.

[23]  T. Mikuls,et al.  Switching anti-TNF-alpha agents: what is the evidence? , 2007, Current rheumatology reports.

[24]  D. De Argila,et al.  [Cost-effectiveness analysis comparing methotrexate with PUVA therapy for moderate-severe psoriasis in the sanitary area of Badajoz]. , 2007, Actas dermo-sifiliograficas.

[25]  K. Mori,et al.  Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[26]  F. Priestap,et al.  Impact of intensive care unit discharge time on patient outcome , 2006, Critical care medicine.

[27]  J. Ajani.  Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Matthias Schneider,et al.  Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. , 2006, Arthritis and rheumatism.

[29]  M. Romano,et al.  Mechanisms of Disease: Helicobacter pylori-related gastric carcinogenesis—implications for chemoprevention , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[30]  E. Keystone.  Switching tumor necrosis factor inhibitors: an opinion , 2006, Nature Clinical Practice Rheumatology.

[31]  M. Sculpher,et al.  Etanercept and efalizumab for the treatment of psoriasis: a systematic review. , 2006, Health technology assessment.

[32]  P Barton,et al.  A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. , 2006, Health technology assessment.

[33]  Daniel B. Shin,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[34]  K. Hess,et al.  Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  N. Davidson,et al.  Assessing the total costs of blood delivery to hospital oncology and haematology patients , 2006, Current medical research and opinion.

[36]  D. Ford,et al.  Work Limitations and Productivity Loss Are Associated with Health-Related Quality of Life but Not with Clinical Severity in Patients with Psoriasis , 2006, Dermatology.

[37]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[38]  S. Shumack,et al.  CLinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate‐to‐severe plaque psoriasis: results from a phase III international randomized, placebo‐controlled trial , 2006, The British journal of dermatology.

[39]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Menter,et al.  Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial , 2006, International journal of dermatology.

[41]  M. Duvic,et al.  The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. , 2006, Journal of the American Academy of Dermatology.

[42]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[43]  H. Richards,et al.  Adherence to treatment in patients with psoriasis , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  John D Santamaria,et al.  After‐hours discharges from intensive care are associated with increased mortality , 2006, The Medical journal of Australia.

[45]  N. Reynolds,et al.  Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial , 2006, The Lancet.

[46]  J. Fowler,et al.  Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. , 2006, Journal of the American Academy of Dermatology.

[47]  T. Agner,et al.  Quality of life and depression in a population of occupational hand eczema patients , 2006, Contact dermatitis.

[48]  A. Gottlieb,et al.  Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial , 2006, The Lancet.

[49]  S. Feldman,et al.  Adverse events from systemic therapies for psoriasis are common in clinical practice , 2006, The Journal of dermatological treatment.

[50]  Oliver Rivero-Arias,et al.  Estimating the Association between SF-12 Responses and EQ-5D Utility Values by Response Mapping , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[51]  D. Bowen.  Etiology and Epidemiology of MDS , 2006 .

[52]  Michael Hinckley,et al.  Impact of obesity and smoking on psoriasis presentation and management. , 2005, Archives of dermatology.

[53]  P. Greenberg,et al.  Management of patients with higher risk myelodysplastic syndromes. , 2005, Critical reviews in oncology/hematology.

[54]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[55]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[56]  S. Kitano,et al.  Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. , 2005, International journal of oncology.

[57]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.

[58]  R. Shikiar,et al.  Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): Results from patients with chronic idiopathic urticaria , 2005, Health and quality of life outcomes.

[59]  A. Finlay.  Current severe psoriasis and the Rule of Tens , 2005, The British journal of dermatology.

[60]  B. Järvholm,et al.  Fifteen‐year follow‐up of hand eczema: persistence and consequences , 2005, The British journal of dermatology.

[61]  J. Bennett,et al.  The clinical implications of the World Health Organization's classification of myelodysplastic syndromes. , 2005, Current hematology reports.

[62]  S. Lippman,et al.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  A. Gottlieb,et al.  Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. , 2005, Journal of the American Academy of Dermatology.

[64]  B. Dréno,et al.  Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis , 2005, British Journal of Dermatology.

[65]  J. Isola,et al.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  T. Agner,et al.  The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter‐ and intraobserver reliability , 2005, The British journal of dermatology.

[67]  A. Menter,et al.  Cost-efficacy analysis of biological treatments in psoriasis: an 18-month assessment , 2005 .

[68]  T. Agner,et al.  Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema , 2005, The British journal of dermatology.

[69]  W. Förster,et al.  Therapeutic use of the 193-nm excimer laser in corneal pathologies , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.

[70]  J. Winter,et al.  The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study , 2005, Annals of Hematology.

[71]  M. Wetherell,et al.  Opening the box: evaluating the Citizens Council of NICE: report prepared for the National Co-ordinating Centre for Research Methodology, NHS Research and Development Programme , 2005 .

[72]  R. Brand,et al.  Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. , 2005, Haematologica.

[73]  A. Menter,et al.  Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. , 2005, Archives of dermatology.

[74]  S. Feldman,et al.  A Cost Comparison of Treatments of Moderate to Severe Psoriasis , 2005 .

[75]  Bisharah Libbus,et al.  A randomized trial of etanercept as monotherapy for psoriasis , 2005 .

[76]  F. Nestle,et al.  The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. , 2004, The Journal of investigative dermatology.

[77]  E. V. van Sonderen,et al.  Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. , 2004, Archives of dermatology.

[78]  J. Ortonne,et al.  Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. , 2004, Archives of dermatology.

[79]  N. Reynolds,et al.  Guidelines for prescribing azathioprine in dermatology , 2004, The British journal of dermatology.

[80]  D. Arsène,et al.  Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[82]  G. Duke,et al.  Night-shift Discharge from Intensive Care Unit Increases the Mortality-risk of ICU Survivors , 2004, Anaesthesia and intensive care.

[83]  M. Rawlins.  NICE work--providing guidance to the British National Health Service. , 2004, The New England journal of medicine.

[84]  R. Vollenhoven,et al.  Switching between biological agents. , 2004 .

[85]  J. Brazier,et al.  The Estimation of a Preference-Based Measure of Health From the SF-12 , 2004, Medical care.

[86]  L. Naldi,et al.  Overview of studies of treatments for hand eczema—the EDEN hand eczema survey , 2004, The British journal of dermatology.

[87]  J. Saurat,et al.  Biological therapies in the systemic management of psoriasis: International Consensus Conference , 2004, The British journal of dermatology.

[88]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[89]  Nick Freemantle,et al.  Challenges for the National Institute for Clinical Excellence , 2004, BMJ : British Medical Journal.

[90]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[91]  A. Ochiai,et al.  Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  F. Nestle,et al.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. , 2004, The Journal of clinical investigation.

[93]  Haomiao Jia,et al.  Mapping the SF-12 to the EuroQol EQ-5D Index in a National US Sample , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

[94]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[95]  G. Peters,et al.  The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. , 2004, Blood.

[96]  B. Järvholm,et al.  Incidence of hand eczema-a population-based retrospective study. , 2004, The Journal of investigative dermatology.

[97]  R M Stone,et al.  Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome , 2004, Leukemia.

[98]  L. Klareskog,et al.  Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect , 2004, Annals of the rheumatic diseases.

[99]  David J Margolis,et al.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. , 2004, The journal of investigative dermatology. Symposium proceedings.

[100]  P Barton,et al.  The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.

[101]  L. Naldi,et al.  Study Design and Preliminary Results from the Pilot Phase of the PraKtis Study: Self-Reported Diagnoses of Selected Skin Diseases in a Representative Sample of the Italian Population , 2004, Dermatology.

[102]  M. Little.  Setting limits fairly: can we learn to share medical resources? , 2004 .

[103]  Alan Williams,et al.  What Could be Nicer than NICE , 2004 .

[104]  D. Margolis,et al.  Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". , 2004, Journal of the American Academy of Dermatology.

[105]  R. Herbst,et al.  Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. , 2004, Journal of the American Academy of Dermatology.

[106]  R. Chlebowski,et al.  5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma , 2004, Investigational New Drugs.

[107]  M. Lebwohl,et al.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.

[108]  A. Gottlieb,et al.  Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.

[109]  A. Kari,et al.  Ruokonen The effects of ICU admission and discharge times on mortality in Finland , 2003 .

[110]  Y. Tanaka,et al.  981 Antitumor activity of trastuzumab (Herceptin®) in human gastric cancer models , 2003 .

[111]  E. Warshaw,et al.  Hand dermatitis: a review of clinical features, therapeutic options, and long-term outcomes. , 2003, American journal of contact dermatitis : official journal of the American Contact Dermatitis Society.

[112]  B. Diffey.  Factors affecting the choice of a ceiling on the number of exposures with TL01 ultraviolet B phototherapy , 2003, The British journal of dermatology.

[113]  Donald Rudikoff,et al.  The treatment of atopic dermatitis with systemic immunosuppressive agents. , 2003, Clinics in dermatology.

[114]  S. Im,et al.  The Prognostic Significance of the Overexpression of HER-2/ neu in Korean Gastric Carcinomas and the In Vitro Effects of Anti-HER-2/neu Antibody on Cell Growth in the Gastric Carcinoma Cell Lines. , 2003, Cancer research and treatment : official journal of Korean Cancer Association.

[115]  M. Essink‐bot,et al.  Quality of life measurement in patients with transfusion‐dependent myelodysplastic syndromes , 2003, British journal of haematology.

[116]  I. Dybedal,et al.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.

[117]  A. Morrell,et al.  Management of band keratopathy with excimer phototherapeutic keratectomy: visual, refractive, and symptomatic outcome , 2003, Eye.

[118]  Mikael Lundin,et al.  Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[120]  José Luis Sastre Moral,et al.  Incidence and characteristics of myelodysplastic syndromes in Ourense (Spain) between 1994-1998. , 2003, Haematologica.

[121]  H. Fujii,et al.  Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. , 2002, Cancer research.

[122]  Ezekiel J Emanuel,et al.  Quantifying the harmful effect of psoriasis on health-related quality of life. , 2002, Journal of the American Academy of Dermatology.

[123]  J. Berth-Jones,et al.  Azathioprine in severe adult atopic dermatitis: a double‐blind, placebo‐controlled, crossover trial , 2002, The British journal of dermatology.

[124]  T. Peters,et al.  Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers , 2002, The British journal of surgery.

[125]  Dennis F. Thompson,et al.  Deliberative Democracy Beyond Process , 2002 .

[126]  U. Gieler,et al.  Psychological factors associated with hand dermatoses: which subgroup needs additional psychological care? , 2002, The British journal of dermatology.

[127]  W. Allum,et al.  Guidelines for the management of oesophageal and gastric cancer , 2002, Gut.

[128]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  T. Hickish,et al.  Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  B. Järvholm,et al.  Hand eczema in Swedish adults - changes in prevalence between 1983 and 1996. , 2002, The Journal of investigative dermatology.

[132]  E. Cohen,et al.  Phototherapeutic keratectomy versus diamond burr polishing of Bowman's membrane in the treatment of recurrent corneal erosions associated with anterior basement membrane dystrophy. , 2002, Ophthalmology.

[133]  B. Starfield.  Equity in health , 2002, Journal of epidemiology and community health.

[134]  P. McQuillan,et al.  Waiting for the break of dawn? The effects of discharge time, discharge TISS scores and discharge facility on hospital mortality after intensive care. , 2002, Intensive care medicine.

[135]  I. Smith,et al.  Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies , 2001, Anti-cancer drugs.

[136]  J. Bourke,et al.  Guidelines for care of contact dermatitis , 2001, The British journal of dermatology.

[137]  T. Menné,et al.  Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. , 2001, Acta dermato-venereologica.

[138]  R. Stern,et al.  Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study , 2001, The Lancet.

[139]  R. D. Stulting,et al.  Keratolysis following excimer laser phototherapeutic keratectomy in a patient with keratoconus. , 2001, Journal of refractive surgery.

[140]  H. Taylor,et al.  A comparison of different depth ablations in the treatment of painful bullous keratopathy with phototherapeutic keratectomy , 2001, The British journal of ophthalmology.

[141]  U. Chaudhari,et al.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.

[142]  U. Germing,et al.  Epidemiological Features of Myelodysplastic Syndromes: Results From Regional Cancer Surveys and Hospital-Based Statistics , 2001, International journal of hematology.

[143]  Tae Won Kim,et al.  A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-fu (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC) , 2001 .

[144]  D. Jones,et al.  Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. , 2001, Molecular pharmacology.

[145]  M. Lebwohl,et al.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. , 2001, Archives of dermatology.

[146]  T. Oshika,et al.  Iatrogenic keratectasia after phototherapeutic keratectomy , 2001, The British journal of ophthalmology.

[147]  Yao-chang Chen,et al.  Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation , 2001, British journal of haematology.

[148]  J. Ross,et al.  The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract , 2001, Cancer investigation.

[149]  F. Sassi,et al.  Equity and the economic evaluation of healthcare. , 2001, Health technology assessment.

[150]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[151]  Norman Daniels,et al.  Accountability for reasonableness , 2000, BMJ : British Medical Journal.

[152]  P. Dolan,et al.  Principles of justice in health care rationing , 2000, Journal of medical ethics.

[153]  T. Hoang‐Xuan,et al.  [Limbal stem cell deficiency]. , 2000, Journal francais d'ophtalmologie.

[154]  J. Trasler,et al.  Deoxyribonucleic acid hypomethylation of male germ cells by mitotic and meiotic exposure to 5-azacytidine is associated with altered testicular histology. , 2000, Endocrinology.

[155]  E. Van Cutsem,et al.  Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  R. Faden,et al.  Inequalities in Health, Inequalities in Health Care: Four Generations of Discussion about Justice and Cost-Effectiveness Analysis , 2000, Kennedy Institute of Ethics journal.

[158]  B. Daniele,et al.  The role of chemotherapy in the management of gastric cancer. , 2000, Journal of clinical gastroenterology.

[159]  C. Goldfrad,et al.  Consequences of discharges from intensive care at night , 2000, The Lancet.

[160]  D. Gilliland,et al.  Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome , 2000 .

[161]  B. Diffey,et al.  Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group , 2000, The British journal of dermatology.

[162]  H. Williams,et al.  A systematic review of treatments for severe psoriasis. , 2000, Health technology assessment.

[163]  W. Bollag,et al.  Successful Treatment of Chronic Hand Eczema with Oral 9-cis-Retinoic Acid , 1999, Dermatology.

[164]  B. Quesnel,et al.  P15INK4b gene methylation and myelodysplastic syndromes. , 1999, Leukemia & lymphoma.

[165]  Erik Nord,et al.  Cost-Value Analysis in Health Care: Making Sense out of QALYS , 1999 .

[166]  D M Reboussin,et al.  Psoriasis causes as much disability as other major medical diseases. , 1999, Journal of the American Academy of Dermatology.

[167]  E. Cohen,et al.  Recurrence of corneal dystrophy after excimer laser phototherapeutic keratectomy. , 1999, Ophthalmology.

[168]  S. Clark,et al.  Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. , 1999, Cancer research.

[169]  T. Hirao,et al.  The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 1999, Cancer.

[170]  T. Hickish,et al.  Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial , 1999, British Journal of Cancer.

[171]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[172]  P. Guldberg,et al.  Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. , 1999, Cancer research.

[173]  W. Hiddemann,et al.  Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes , 1999, Journal of Cancer Research and Clinical Oncology.

[174]  R. Stern,et al.  Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. , 1998, Archives of dermatology.

[175]  N. Daniels,et al.  The ethics of accountability in managed care reform. , 1998, Health affairs.

[176]  M. Lazzarino,et al.  Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS , 1998, British journal of haematology.

[177]  R. Bhopal,et al.  Spectre of racism in health and health care: lessons from history and the United States , 1998, BMJ.

[178]  B. Quesnel,et al.  Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.

[179]  G. Colloca,et al.  Treatment of patients with advanced gastric carcinoma with a 5‐fluorouracil‐based or a cisplatin‐based regimen , 1998, Cancer.

[180]  Y. Morad,et al.  Excimer laser phototherapeutic keratectomy for recurrent corneal erosion , 1998, Journal of cataract and refractive surgery.

[181]  F. Bauduer,et al.  Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. , 1998, Leukemia research.

[182]  L Adorini,et al.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.

[183]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[184]  M. Johannesson,et al.  Is the valuation of a QALY gained independent of age? Some empirical evidence. , 1997, Journal of health economics.

[185]  N. Daniels,et al.  Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. , 1997, Philosophy & public affairs.

[186]  R. Krueger,et al.  Topical diclofenac sodium after excimer laser phototherapeutic keratectomy. , 1997, Journal of refractive surgery.

[187]  H. Grossniklaus,et al.  Increased corneal scarring after phototherapeutic keratectomy in Fuchs' corneal dystrophy. , 1997, Journal of refractive surgery.

[188]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[189]  J. R. Simons,et al.  A left–right comparison of UVB phototherapy and topical photochemotherapy in bilateral chronic hand dermatitis after 6 weeks' treatment , 1997, Clinical and experimental dermatology.

[190]  T. Kinoshita,et al.  Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. , 1997, Blood.

[191]  E. Donnenfeld,et al.  Excimer laser phototherapeutic keratectomy. , 1997, Cornea.

[192]  A. Wahba-Yahav.  Disease concomitance in psoriasis. , 1996, Journal of the American Academy of Dermatology.

[193]  S. Reitamo,et al.  Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. , 1996, Acta dermato-venereologica.

[194]  H. Sachs,et al.  Excimer laser phototherapeutic keratectomy for recurrent erosions: a clinical study. , 1996, Ophthalmic surgery and lasers.

[195]  R. Maloney,et al.  A prospective multicenter trial of excimer laser phototherapeutic keratectomy for corneal vision loss. The Summit Phototherapeutic Keratectomy Study Group. , 1996, American journal of ophthalmology.

[196]  T. Petrella,et al.  Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. , 1996, British Journal of Cancer.

[197]  J. Saurat,et al.  Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings. , 1996, Journal of the American Academy of Dermatology.

[198]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[199]  J. Cameron,et al.  Wessely‐type immune ring following phototherapeutic keratectomy , 1996, Journal of cataract and refractive surgery.

[200]  A. Bird.  The relationship of DNA methylation to cancer. , 1996, Cancer surveys.

[201]  J. Geiger,et al.  Oral 9-cis-retinoic acid versus 13-cis-retinoic acid in acne therapy. , 1996, Dermatology.

[202]  G. Colucci,et al.  Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. , 1995, American journal of clinical oncology.

[203]  R. Maloney.  Treatment of corneal dystrophies with excimer laser. , 1995, Survey of ophthalmology.

[204]  A. Bhagwat,et al.  The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. , 1995, The Biochemical journal.

[205]  Alain Boyer.  Democracy and Disagreement , 1995 .

[206]  M. Carlsson,et al.  Incidence of myelodysplastic syndromes in a Swedish population , 1995, European journal of haematology.

[207]  N. Scheinfeld.  Principles of Health Care Ethics , 1995, The Yale Journal of Biology and Medicine.

[208]  M. J. Phillips,et al.  ESTABLISHING THE INCIDENCE OF MYELODYSPLASIA SYNDROME , 1994, British Journal of Haematology.

[209]  D. Oscier,et al.  Establishing the incidence of myelodysplastic syndrome. , 1994, British journal of haematology.

[210]  R Gillon,et al.  Medical ethics: four principles plus attention to scope , 1994, BMJ.

[211]  R. Stern,et al.  The carcinogenic risk of treatments for severe psoriasis , 1994, Cancer.

[212]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[213]  D. Gartry,et al.  Treatment of band keratopathy by excimer laser phototherapeutic keratectomy: surgical techniques and long term follow up. , 1993, The British journal of ophthalmology.

[214]  P. Norris,et al.  Oral psoralen photochemotherapy in severe childhood atopic eczema: an update , 1993, The British journal of dermatology.

[215]  N. Yamanaka,et al.  Relationship of C‐erbB‐2 protein expression and gene amplification to invasion and metastasis in human gastric cancer , 1993, Cancer.

[216]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.

[217]  A. Burdorf,et al.  Prevalence of hand dermatitis in different occupations. , 1993, International journal of epidemiology.

[218]  P. Tugwell,et al.  Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. , 1993, The Journal of rheumatology.

[219]  S. Hirohashi,et al.  Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. , 1993, Cancer.

[220]  N. Gattermann,et al.  Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes , 1992, British journal of haematology.

[221]  P. Ritch,et al.  Evaluation of continuous infusion low‐dose 5‐azacytidine in the treatment of myelodysplastic syndromes , 1991, American journal of hematology.

[222]  D C Hadorn,et al.  Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. , 1991, JAMA.

[223]  D C Brown,et al.  Clinical use of the 193-nm excimer laser in the treatment of corneal scars. , 1991, Archives of ophthalmology.

[224]  B. Berry,et al.  Cisplatin therapy for adenocarcinoma of the stomach. , 1991, Seminars in oncology.

[225]  A. Carmichael,et al.  Comparison of topical PUVA with UVA for chronic vesicular hand eczema , 1989, Acta dermato-venereologica.

[226]  B. Meding,et al.  Consequences of having hand eczema , 1990, Contact dermatitis.

[227]  Terry J. Hamblin,et al.  Leukaemia and Lymphoma—an atlas of distribution within areas of England and Wales, 1984–1988 , 1990 .

[228]  G. Swanbeck,et al.  Epidemiology of different types of hand eczema in an industrial city. , 1989, Acta dermato-venereologica.

[229]  J S Carey,et al.  Philosophical Medical Ethics , 1987 .

[230]  B. Leyland-Jones,et al.  Biochemistry of azacitidine: a review. , 1987, Cancer treatment reports.

[231]  G. Swanbeck,et al.  Chronic eczematous dermatitis of the hands: a comparison of PUVA and UVB treatment. , 1987, Acta dermato-venereologica.

[232]  T. Kuroki,et al.  Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. , 1986, Journal of the National Cancer Institute.

[233]  M. Tattersall,et al.  Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[234]  F. di Costanzo,et al.  Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC). , 1986, Cancer treatment reports.

[235]  T. Fleming,et al.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. , 1985, JAMA.

[236]  P. Barr,et al.  On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs , 1983, Cell.

[237]  V. Wilson,et al.  Inhibition of DNA methylation by 5-azacytidine. , 1983, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[238]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[239]  L H Li,et al.  Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. , 1970, Cancer research.

[240]  L. Li,et al.  Phase specificity of 5-azacytidine against mammalian cells in tissue culture. , 1970, Cancer research.

[241]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[242]  S. Seeber,et al.  CHEMOTHERAPY OF GASTRIC CANCER. , 1964, Acta - Unio Internationalis Contra Cancrum.

[243]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[244]  D.,et al.  Regression Models and Life-Tables , 2022 .